Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA flags potential VEGF-related safety concern in Summit rejection letter

The FDA flagged a safety issue in its review of Summit Therapeutics’ and Akeso's now-rejected cancer drug ivonescimab, raising questions about the viability of the whole class of new bispecifics, though the ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Tuesday 17 November →